GlassScriptPhysician profile
Mimi Ngoc-Anh Phan
NPI 1093035610
$8,592.60
in general payments reported to CMS, 2019-2025
37 companies · $2,987 in 2025
The $2,987 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $520 · 2020: $251 · 2021: $223 · 2022: $809 · 2023: $1,541 · 2024: $2,262 · 2025: $2,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,756 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,755.76 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,655.90 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $980.07 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Electromed, INC. | $903.92 | 2021-2025 | Smartvest |
| Genzyme Corporation | $798.80 | 2024-2025 | |
| Mylan Specialty L.P. | $581.02 | 2020-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $525.86 | 2019-2025 | Dupixent |
| Amgen INC. | $342.33 | 2022-2025 | Tezspire, Tavneos |
| Insmed, INC. | $243.34 | 2022-2025 | Arikayce, Brinsupri |
| Revance Therapeutics, INC. | $206.65 | 2024 | Daxxify |
| Verona Pharma, INC. | $174.22 | 2025 | Ohtuvayre |
| Genentech USA, INC. | $172.25 | 2019 | |
| Abbvie INC. | $162.12 | 2021-2025 | |
| Inspire Medical Systems, INC. | $147.87 | 2025 | Inspire |
| Pulmonx Corporation | $146.04 | 2023 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $144.18 | 2020-2025 | Aralast, Eohilia, Gattex |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.35 | 2019-2025 | Jascayd, Ofev, Spiriva Respimat |
| Optinose US, INC. | $139.53 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $107.06 | 2021-2023 | Xarelto |
| Philips North America LLC | $106.79 | 2019-2025 | (2383) Sleepundivided, Vest Therapy Und |
| Inogen, INC. | $101.60 | 2022-2025 | |
| Shionogi INC | $97.83 | 2023-2025 | Fetroja |
| Merck Sharp & Dohme LLC | $96.58 | 2020 | |
| Octapharma USA, INC. | $78.13 | 2024 | Panzyga |
| Grifols USA, LLC | $70.18 | 2021-2025 | Prolastin-C Liquid |
| Sunovion Pharmaceuticals INC. | $69.10 | 2019-2020 | |
| Viatris Specialty LLC | $66.30 | 2025 | Yupelri |
| Allergan, INC. | $46.10 | 2019 | |
| United Therapeutics Corporation | $41.70 | 2022-2025 | Tyvaso |
| Paratek Pharmaceuticals, INC. | $40.63 | 2023-2024 | Nuzyra |
| Ambu INC. | $39.41 | 2020 | |
| Tactile Systems Technology INC | $35.63 | 2024 | Entre Plus, Flexitouch Plus |
| Novartis Pharmaceuticals Corporation | $26.60 | 2021-2024 | |
| Biofrontera INC. | $23.03 | 2022 | |
| Liquidia Technologies, INC. | $22.52 | 2025 | Yutrepia |
| Teva Pharmaceuticals USA, INC. | $21.49 | 2023 | Airduo Digihaler |
| Arbor Pharmaceuticals, INC. | $19.81 | 2022 | |
| Kaleo, INC. | $17.66 | 2024 | Auvi-Q |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mimi Phan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.